UNSPSC 51161544: Lomifylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C13H18N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NA91GV8GDJ, chemically known as 1,2,3,6-tetrahydro-1,3-dimethyl-7-(5-oxohexyl)purin-2,6-dion but generally known as lomifylline, which bears US NIH Compound Identifier 65599. European Medicines Agency schedules Lomifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08566MIG.

UNSPSC 51161544 Lomifylline is a Commodity code covering pharmaceutical product sourcing by state and local health systems and cooperative purchasing alliances. State and local governments use this code to procure specific branded and generic pharmaceuticals through centralized purchasing agreements with manufacturers and authorized wholesalers. The scope of work includes negotiating pricing, product availability, and supply-chain compliance for individual drug products identified by National Drug Code (NDC), with vendors required to maintain relationships with authorized pharmaceutical wholesalers, certify compliance with cGMP and the Drug Supply Chain Security Act, carry substantial insurance coverage (commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000), and meet FDA requirements. Issuing bodies under this code include state health departments, multistate cooperative purchasing alliances, and member facilities across participating states. Evaluation typically emphasizes price competitiveness, with secondary weight on administrative compliance, EDI capability, and pricing flexibility options.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with response due March 26, 2026 and a cutoff for questions on February 18, 2026. The RFP weights evaluation at 75 percent price competitiveness, 10 percent fixed pricing, 5 percent EDI capability, 5 percent administrative fee format compliance, and 5 percent pricing structure flexibility (flat price, net price formats, or WAC-minus structures). Awarded vendors will be provided to authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) by May 15, 2026, with contract effectiveness on July 1, 2026. The agreement term runs two years for new responders with optional extensions, while incumbent amendments align through June 30, 2028. This multistate cooperative vehicle spans Minnesota and Oregon, with procurement administered through the ePro system and submissions to MMCAP_Infuse.RFP@state.mn.us.